Meeting abstract
https://doi.org/10.26800/LV-144-supl2-CM05
TOCILIZUMAB treatment in COVID-19
Lucija Vusić
; School of Medicine University of Zagreb
Marija Gomerčić Palčić
; Department of pulmology, Sestre milosrdnice University Hospital Center Zagreb
Abstract
Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL- 6) receptor. It is found that IL‐6 is one of the most important cytokines involved in COVID‐19‐induced cytokine storms and its higher levels are found in critically ill patients with COVID-19. Real‐life data about the effect of TCZ on the inflammatory activity in COVID‐19 patients as well as its side effects are still missing.
Keywords
COVID-19, interleukin-6, tocilizumab
Hrčak ID:
279928
URI
Publication date:
27.4.2022.
Visits: 278 *